Vireo Growth (VREOF) Amortizatization of Intangibles (2020 - 2025)
Vireo Growth (VREOF) posted Amortizatization of Intangibles of $415285.0 for Q4 2025, up 628.37% sequentially from $57016.0 in Q3 2025, and up 690.33% YoY from $52546.0 in Q4 2024.
Vireo Growth (VREOF) Amortizatization of Intangibles (2020 - 2025) Analysis & Trends
Vireo Growth has reported Amortizatization of Intangibles for 6 years, with the latest figure at $415285.0 in Q4 2025.
- Quarterly Amortizatization of Intangibles rose 690.33% year-over-year to $415285.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $575677.0 (up 160.48% YoY) and the FY2025 annual result came in at $575677.0, up 160.48% from the prior year.
- Amortizatization of Intangibles improved to $415285.0 in Q4 2025 per VREOF's latest filing, from $57016.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.6 million in Q4 2021 and troughed at $3376.0 in Q2 2025.
- A 5-year average of $385158.0 and a median of $154884.5 in 2021 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2021 and 2025: Amortizatization of Intangibles soared 5676.19% in 2021, then plunged 93.98% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $1.6 million in 2021, then plunged by 64.7% to $572473.0 in 2022, then slumped by 66.07% to $194262.0 in 2023, then plunged by 72.95% to $52546.0 in 2024, then soared by 690.33% to $415285.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $415285.0, $57016.0, and $3376.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 415,285.00 |
| Dec 31, 2025 | 415,285.00 |
| Sep 30, 2025 | 57,016.00 |
| Sep 30, 2025 | 57,016.00 |
| Jun 30, 2025 | 3,376.00 |
| Jun 30, 2025 | 3,376.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 52,546.00 |
| Dec 31, 2024 | 52,546.00 |
| Sep 30, 2024 | 59,562.00 |
| Sep 30, 2024 | 59,562.00 |
| Jun 30, 2024 | 56,087.00 |
| Jun 30, 2024 | 56,087.00 |
| Mar 31, 2024 | 52,815.00 |
| Mar 31, 2024 | 52,815.00 |
| Dec 31, 2023 | 194,262.00 |
| Dec 31, 2023 | 194,262.00 |
| Sep 30, 2023 | 207,329.00 |
| Sep 30, 2023 | 207,329.00 |